AB Science SA (ABS.PA) News| Reuters.com
Edition:
United States

AB Science SA (ABS.PA)

ABS.PA on Paris Stock Exchange

13.00EUR
24 Jun 2016
Change (% chg)

€-0.89 (-6.41%)
Prev Close
€13.89
Open
€11.60
Day's High
€13.30
Day's Low
€11.50
Volume
240,609
Avg. Vol
167,203
52-wk High
€19.90
52-wk Low
€8.62

Select another date:

Mon, Jun 6 2016

BRIEF-AB Science: Rapporteurs appointed by EMA have recommended filing of masitinib in ALS for conditional marketing authorization

* Rapporteurs appointed by EMA have recommended filing of masitinib in amyotrophic lateral sclerosis (ALS) for conditional marketing authorization

BRIEF-Ab Science submits to EMA the marketing authorization application for masitinib

* Has submitted to EMA the marketing authorization application for masitinib in the treatment of severe systemic mastocytosis

BRIEF-AB Science FY operating loss widens to 26.0 million euros

* FY revenue 2.3 million euros ($2.63 million) versus 2.1 million euros year ago

BRIEF-Ab Science announces success of a private placement

* Twelve million euro ($13.5 million) raised through a private placement of 764,820 shares

BRIEF-Ab Science launches share capital increase

* Said on Sunday, it launched a share capital increase by way of accelerated book building

BRIEF-AB Science announces positive interim results from phase 3 trial of masitinib

* AB Science announces positive interim results from phase 3 trial of masitinib in amyotrophic lateral sclerosis (ALS)

BRIEF-Ab Science underscores potential of masitinib in neurological and neurodegenerative diseases

* New independent publications underscore the potential of masitinib in neurological and neurodegenerative diseases Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Ab Science will present data at the international symposium on advances in Alzheimer therapy

* Will present new preclinical and clinical data at the international symposium on advances in Alzheimer therapy

BRIEF-AB Science updates on marketing authorization for masitinib

* Announces that Rapporteurs appointed by the EMA have recommended to file a marketing authorization application for full approval for masitinib in severe systemic mastocytosis

Select another date: